loading
Precedente Chiudi:
$27.50
Aprire:
$27.59
Volume 24 ore:
76,442
Relative Volume:
0.14
Capitalizzazione di mercato:
$1.58B
Reddito:
$1.23M
Utile/perdita netta:
$-185.98M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-156.42M
1 W Prestazione:
-13.08%
1M Prestazione:
-16.19%
6M Prestazione:
-24.69%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$26.76
$29.09
Intervallo di 1 settimana:
Value
$25.74
$31.35
Portata 52W:
Value
$10.42
$47.97

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
Nome
Spyre Therapeutics Inc
Name
Telefono
(617) 651-5940
Name
Indirizzo
221 CRESCENT STREET, WALTHAM
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SYRE's Discussions on Twitter

Confronta SYRE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
SYRE 27.18 1.58B 1.23M -185.98M -156.42M 0.00
VRTX 448.33 115.74B 10.63B -479.80M -1.35B 13.33
REGN 744.13 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.33 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.98 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.75 24.49B 3.30B -501.07M 1.03B 11.54

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-20 Iniziato BTIG Research Buy
2023-12-11 Iniziato Guggenheim Buy
2023-12-11 Iniziato Jefferies Buy
2020-05-04 Iniziato Piper Sandler Overweight
2019-03-21 Iniziato JP Morgan Overweight
2018-09-04 Downgrade Wells Fargo Outperform → Market Perform
2018-04-24 Iniziato Evercore ISI Outperform
2018-03-14 Reiterato Needham Buy
Mostra tutto

Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie

pulisher
Nov 20, 2024

First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq

Nov 20, 2024
pulisher
Nov 20, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire

Nov 20, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics revises net loss per share calculations - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics launches $200 million public offering - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

SYRE Crosses Below Key Moving Average Level - Nasdaq

Nov 14, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre reports promising Phase 1 results for IBD therapy - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 07, 2024
pulisher
Nov 03, 2024

292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Nov 01, 2024
pulisher
Oct 30, 2024

Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics director sells shares worth $10,929 - Investing.com India

Oct 29, 2024
pulisher
Oct 28, 2024

Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews

Oct 26, 2024
pulisher
Oct 25, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Oct 25, 2024
pulisher
Oct 18, 2024

SPY-003, an extended half-life MAb with twice-a-year projected human maintenance dosing - BioWorld Online

Oct 18, 2024
pulisher
Oct 18, 2024

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Wedbush’s latest rating for SYRE stock - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics Advances SPY003 for IBD Treatment - TipRanks

Oct 15, 2024
pulisher
Oct 14, 2024

Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK

Oct 14, 2024

Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):